1. Clinical Trials in Residual Cardiovascular Risk: A Fresh Perspective

2. Substantial Residual Cardiovascular Risk After Intensive Statin Therapy Post-ACS

3. 47-Year-Old Man: Recent ACS

4. 47-Year-Old Man: Recent ACS (cont)

5. Risk of Major CV Event by LDL and Non-HDL-C Categories

6. 47-Year-Old Man: Treatment Decision

7. 47-Year-Old Man: Treatment Decision

8. AIM-HIGH: Baseline Lipids (mg/dL)

9. 47-Year-Old Man: Treatment Decision

10. 47-Year-Old Man: Treatment Decision

11. SANDS: Effect of Aggressive vs Standard Lipid Goals on CIMT

12. 47-Year-Old Man: Treatment Decision

13. GISSI-Prevenzione: Effect of n-3 PUFAs 1 g/d on CV Outcomes

14. PROVE-IT: Effect of Intensive vs Standard Therapy on Change in LDL-C at 4 Months

15. Non-HDL-C vs LDL-C: Predicting All-Cause Mortality

16. 55-Year-Old Woman With T2DM

17. 55-Year-Old Woman (cont)

18. 55-Year-Old Woman With T2DM

19. ADVENT: Niacin and Blood Glucose in T2DM

20. 55-Year-Old Woman With T2DM

21. FIELD: Effect of Fenofibrate on the Need for Laser Treatment for Diabetic Retinopathy

22. 55-Year-Old Woman With T2DM

23. 55-Year-Old Woman With T2DM

24. COMBOS: Change in Lipid Parameters

25. Program Summary

26. Abbreviations

27. Abbreviations

28. Abbreviations